Materials And Products Tenders

Open House Drug Discount Agreements Oxycodone and Naloxone, Atc N02aa55

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fondaparinux, Atc B01ax05 for the Period June 1St, 2024 - May 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ganirelix, Atc H01cc01 for the Period June 1St, 2024 - May 31St, 2026

Open House Drug Discount Agreements Fampridine, Atc N07xx07

Open House Drug Discount Agreements Valproic Acid, in Non-Sustained-Release Dosage Form, Atc N03ag01

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bexarotene, Atc L01xf03 for the Period June 1St, 2024 - May 31St, 2026

Open House Drug Discount Agreements Dimethyl Fumarate, Atc L04ax07

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Tobramycin (J01gb01) as Part of a So-Called Open House Model.

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Octreotide (Atc Code According to Who: H01cb02)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Fampridine (Atc Code According to Who: N07xx07)